drugset / Trial / NCT05406999
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Phase 2
Recruiting
900 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.
Timeline
- Start
- 2020-02-01
- Primary completion
- 2026-12-31
- Completion
- 2030-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Subject | Apalutamide | Small molecule | 240 mg | Oral |
| Subject | Darotamide | Unknown | 600 mg | Oral |
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | Fluzoparib | Small molecule | — | — |
| Subject | Olaparib | Small molecule | — | — |
| Subject | Pamiparib | Small molecule | — | — |
| Subject | Rezvilutamide | Small molecule | 240 mg | Oral |
| Subject | Talazoparib | Small molecule | — | — |
| Background | Goserelin | Other / unclassified | — | — |
| Background | Leuprolide | Other / unclassified | — | — |
| Background | Prednisolone | Other / unclassified | 5 mg | Oral |
| Background | Triptorelin | Other / unclassified | — | — |
| Background | digareke | Unknown | — | — |